Flax Pond Capital LLC bought a new position in Organogenesis (NASDAQ:ORGO – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund bought 424,191 shares of the company’s stock, valued at approximately $2,197,000.
A number of other large investors have also made changes to their positions in the company. First Light Asset Management LLC boosted its stake in Organogenesis by 10.6% in the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after purchasing an additional 720,748 shares during the period. Assenagon Asset Management S.A. raised its stake in Organogenesis by 14.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after purchasing an additional 680,392 shares during the period. Deutsche Bank AG raised its stake in Organogenesis by 0.4% during the 4th quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after purchasing an additional 13,301 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Organogenesis by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock valued at $9,259,000 after purchasing an additional 62,346 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Organogenesis in the fourth quarter valued at $5,686,000. Institutional investors and hedge funds own 49.57% of the company’s stock.
Organogenesis Price Performance
ORGO stock opened at $2.44 on Friday. Organogenesis has a 12-month low of $2.04 and a 12-month high of $7.08. The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05. The company has a market cap of $313.98 million, a price-to-earnings ratio of -12.84 and a beta of 1.32. The company has a 50 day moving average of $2.46 and a two-hundred day moving average of $3.36.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. Truist Financial assumed coverage on Organogenesis in a research report on Thursday, May 28th. They issued a “hold” rating and a $3.00 target price for the company. Wall Street Zen raised Organogenesis from a “strong sell” rating to a “sell” rating in a research report on Saturday. UBS Group set a $3.00 price objective on Organogenesis in a research note on Thursday, May 28th. Weiss Ratings lowered Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, BTIG Research cut Organogenesis from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.75.
View Our Latest Research Report on Organogenesis
Organogenesis Company Profile
Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.
Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.
Featured Articles
- Five stocks we like better than Organogenesis
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis (NASDAQ:ORGO – Free Report).
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
